by Bruce Sylvester: Patients with grade 2 glioma who received radiation therapy plus PCV chemotherapy (procarbazine, lomustine and vincristine) have achieved longer progression-free survival and overall survival than… read more.
by Gary Finnegan: Good news in the battle against cancer: death rates from leukaemia among people of all ages in Europe are falling.
Role of minimal residual disease in treatment tailoring divides experts by Thomas R. Collins Minimal residual disease (MRD) is a guide for tailoring multiple myeloma whose time has… read more.
by Thomas R. Collins: There could be a role for consolidation autologous stem cell transplantation for patients with diffuse, aggressive non-Hodgkin lymphomas (NHL) who are at high risk… read more.
by Thomas R. Collins: Trials are continuing to explore potential new settings for daratumumab and elotuzumab, two monoclonal antibodies that were recently approved for use in multiple myeloma… read more.
by Bruce Sylvester: Surgical resection is a safe and helpful treatment option for a broad range of patients with early-stage lung cancer, researchers reported online on Nov. 10,… read more.
by Bruce Sylvester: Men who have had a heart attack and then receive androgen deprivation therapy (ADT) for prostate cancer are at an increased risk of subsequent fatal… read more.
by Gary Finnegan: Netherlands: Women with breast cancer who follow a physical exercise programme during their chemotherapy treatment experience fewer side effects, according a study by the Netherlands… read more.
by Bruce Sylvester: Among patients with metastatic hormone-sensitive prostate cancer, chemotherapy with docetaxel at the start of androgen deprivation therapy (ADT) has resulted in an increased survival of… read more.
by Bruce Sylvester: Oral contraceptive use appears to provide long-term protection against endometrial cancer, researchers reported on August 4, 2015 in The Lancet Oncology.
Daily bathing of pediatric patients with disposable cloths containing 2 percent chlorhexidine gluconate (CHG) reduced central line-associated bloodstream infections (CLABSIs) by 59 percent and saved approximately $300,000 in… read more.
by Bruce Sylvester: Rociletinib, an investigative therapy for treatment resistant EGFR-mutation driven lung tumors, shows activity against the most common resistance mutation, and it significantly improves clinical outcomes.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
